Loading clinical trials...
Loading clinical trials...
Detection of Human Beta Cell Death in T1DM by Methylation Specific PCR
To investigate the use of methylation-specific PCR (MSP) assays to detect human beta cell-specific gene methylation patterns in serial blood samples drawn from newly diagnosed Type 1 diabetics.
The study will follow 25 newly diagnosed type 1 diabetic patients from the onset of symptoms to one year post-diagnosis. A total of 11 fasting blood draws will be taken, the first near the time of diabetes diagnosis, then 2 weeks later, monthly for the next 6 months, and every other month until 12 months. Each blood sample will be evaluated by the MSP assay, as well as for measurement of fasting plasma glucose, HbA1c, c-peptide, and autoantibodies. The study will also need 25 healthy volunteers to help us match some DNA markers needed for this data. Healthy volunteers will be se=matched healthy individuals who have one blood sample drawn.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
City of Hope National Medical Center-Department of Diabetes, Endocrinology, & Metabolism
Duarte, California, United States
Loma Linda Medical Center
Loma Linda, California, United States
Start Date
July 1, 2009
Primary Completion Date
April 1, 2015
Completion Date
April 1, 2015
Last Updated
May 1, 2015
6
ACTUAL participants
Blood draw
PROCEDURE
Lead Sponsor
City of Hope Medical Center
NCT07051005
NCT06390371
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03228732